• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation
Stroke prediction scores have not been validated in patients with cancer and Atrial Fibrillation (AF). We aimed to identify unique risk factors and evaluate validity of CHADS2 and CHA2DS2-VASc scores to predict risk of stroke and mortality. A retrospective review of all cancer patients with pre-existing AF presenting from 2008 to 2014 was performed. Outcomes included ischemic stroke and mortality. Prognostic factors were identified with Fine& Gray regression for stroke and Cox proportional hazards analysis for survival.
Source: The American Journal of Cardiology - September 19, 2017 Category: Cardiology Authors: Rushad Patell, Alejandra Gutierrez, Lisa Rybicki, Alok A. Khorana Source Type: research

Risk of Cardioembolic Stroke in Cancer Patients with Atrial Fibrillation
In a recent article in the journal, Elbadawi et al1 find that the risk of cerebrovascular accidents (CVA) in cancer patients with atrial fibrillation (AF) was lower than in non-cancer patients with AF. At first glance this may appear surprising in light of the higher risk of stroke of cancer patients generally2,3, particularly those with aggressive subtypes and/or metastatic disease. However, recent studies in patients with AF and cancer4,5 show no increase in stroke risk, seemingly indicating that the risk of cardioembolic stroke specifically is not higher than in cancer-free pacients.
Source: The American Journal of Cardiology - April 18, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Juan-Manuel Sancho, Elisa Orna Source Type: research

Risk of Cardioembolic Stroke in Patients With Cancer and Atrial Fibrillation
In a recent article in the journal, Elbadawi et al1 find that the risk of cerebrovascular accidents (CVA) in patients with cancer and atrial fibrillation (AF) was lower than in patients with AF without cancer. At first glance, this may appear surprising in light of the higher stroke risk of patients with cancer in general,2,3 particularly those with aggressive subtypes and/or metastatic disease. However, recent studies in patients with AF and cancer4,5 show no increase in stroke risk, seemingly indicating that the risk of cardioembolic stroke specifically is not higher than in patients without cancer.
Source: The American Journal of Cardiology - April 18, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Juan-Manuel Sancho, Elisa Orna Source Type: research

Relation between Cancer and Atrial Fibrillation (from The REasons for Geographic And Racial Differences in Stroke Study)
Atrial fibrillation (AF) is common in patients with life threatening cancer and those undergoing active cancer treatment. However, data from persons with a history of non-life threatening cancer and those who do not require active cancer treatment are lacking. A total of 15,428 (mean age: 66 ± 8.9 years; 47% women; 45% blacks) participants from the REasons for Geographic And Racial Differences in Stroke (REGARDS) with baseline data on prior cancer diagnosis and AF were included. Participants with life threatening cancer and active cancer treatment within 2 years of study enrollment were excluded.
Source: The American Journal of Cardiology - January 31, 2015 Category: Cardiology Authors: Wesley T. O’Neal, Susan G. Lakoski, Waqas Qureshi, Suzanne E. Judd, George Howard, Virginia Howard, Mary Cushman, Elsayed Z. Soliman Source Type: research

Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer.
Rivaroxaban is broadly used for the primary prevention of stroke and systemic embolism in the general population with non-valvular atrial fibrillation (AF). However, there is little published evidence on the safety and efficacy of rivaroxaban for AF in patients with active cancer. The aim of this study was to assess the safety and efficacy of rivaroxaban in patients with active cancer and AF. Use of rivaroxaban in cancer patients at Memorial Sloan Kettering Cancer Center (MSKCC) is monitored in the setting of a Quality Assessment Initiative.
Source: The American Journal of Cardiology - April 26, 2017 Category: Cardiology Authors: Eva S. Laube, Anthony Yu, Dipti Gupta, Yimei Miao, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A. Soff, Simon Mantha Source Type: research

Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer
Rivaroxaban is broadly used for the primary prevention of stroke and systemic embolism in the general population with nonvalvular atrial fibrillation (AF). However, there is little published evidence on the safety and efficacy of rivaroxaban for AF in patients with active cancer. The aim of this study was to assess the safety and efficacy of rivaroxaban in patients with active cancer and AF. The use of rivaroxaban in patients with cancer at the Memorial Sloan Kettering Cancer Center is monitored in the setting of a Quality Assessment Initiative.
Source: The American Journal of Cardiology - April 26, 2017 Category: Cardiology Authors: Eva S. Laube, Anthony Yu, Dipti Gupta, Yimei Miao, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A. Soff, Simon Mantha Tags: Arrhythmias and Conduction Disturbances Source Type: research

Anticoagulant Agents for Atrial Fibrillation in Cancer Patients
In a recent article in the journal, Patell et  al1 found CHADS2 (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke/transient ischemic attack/thromboembolism) and CHA2DS2VASC (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke/transient ischemic attack/thromboembolism, vascular disease, age 65-74, sex category [i.e., female]) to predict risk of ischemic stroke in cancer patients with baseline atrial fibrillation (AF). Although only 36% of patients received anticoagulant therapy, the risk of stroke generally appeared to be lower than in cancer-free individuals.
Source: The American Journal of Cardiology - February 3, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Mireia Santos-Gomez, Elisa Orna Source Type: research

Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events
In conclusion, clinical trial evidence demonstrating the efficacy and safety of LDL cholesterol lowering to a very low level is essential to ascertain the benefits and risks in reducing the residual risk of vascular disease.
Source: The American Journal of Cardiology - February 1, 2013 Category: Cardiology Authors: John C. LaRosa, Terje R. Pedersen, Ransi Somaratne, Scott M. Wasserman Tags: Review Source Type: research

Cardiovascular Care for Women: The 10-Q Report and Beyond
Abstract: According to The National Coalition for Women's Health Research's 10Q Report: Advancing women's heart health through improved research, diagnosis, and treatment published in June 2011, cardiovascular disease (CVD), a term used to describe diseases of the heart or blood vessels, is the leading cause of death for women in the United States, causing more than 420,000 deaths among women annually. Experts estimate that one in two women will die of heart disease or stroke compared with one in 25 women who will die of breast cancer. Despite the fact that more women than men die each year of heart disease and that there...
Source: The American Journal of Cardiology - August 1, 2013 Category: Cardiology Authors: Nanette K. Wenger, Sharonne N. Hayes, Carl J. Pepine, William C. Roberts Tags: Multimedia Activities Source Type: research

Utility of Global Longitudinal Strain by Echocardiography to Detect Left Ventricular Dysfunction in Long-Term Adult Survivors of Childhood Lymphoma and Acute Lymphoblastic Leukemia
Measuring left ventricular (LV) global longitudinal strain (GLS) is recommended in screening of long-term cancer survivors for cardiotoxicity. However, there are limited data on GLS in this setting, in particular in survivors with apparently normal LV function without risk factors of impaired GLS. In the present study, we measured GLS in 191 adult survivors of childhood lymphoma or acute lymphoblastic leukemia, with normal LV ejection fraction (EF) and fractional shortening (FS), and without known hypertension, diabetes mellitus, myocardial infarction or stroke.
Source: The American Journal of Cardiology - May 13, 2016 Category: Cardiology Authors: Jon R. Christiansen, Richard Massey, Håvard Dalen, Adriani Kanellopoulos, Hanne Hamre, Sophie D. Fosså, Ellen Ruud, Cecilie E. Kiserud, Svend Aakhus Source Type: research

Effect of Bleeding Risk on Type of Stent Used in Patients Presenting with Acute Coronary Syndrome
Patients at high bleeding risk (HBR) are at increased risk of bleeding following percutaneous coronary intervention (PCI) with drug-eluting stent (DES) due to the need for longer dual antiplatelet duration. We sought to evaluate the likelihood of receiving DES during PCI in HBR populations and to characterize DES utilization trends over time. Consecutive patients who underwent PCI from April 2003 to September 2015 were identified. HBR is defined as patients fulfilling one or more of the HBR criteria: age ≥75 years, anticoagulation use at discharge, history of stroke, cancer in previous 3 years, glucocorticoid use, hemoglobin (Hgb)
Source: The American Journal of Cardiology - July 24, 2017 Category: Cardiology Authors: M. Chadi Alraies, Sang Yeub Lee, Michael J. Lipinski, Kyle Buchanan, Arie Steinvil, Toby Rogers, Edward Koifman, Jiaxiang Gai, Rebecca Torguson, Itsik Ben-Dor, Lowell F. Satler, Augusto D. Pichard, Ron Waksman Source Type: research

Relation of Platelet Parameters with Incident Cardiovascular Disease (The Dongfeng-Tongji Cohort Study)
This study aimed to investigate the above-mentioned prospective relations in the middle-aged and older Chinese populations based on the Dongfeng-Tongji (DFTJ) cohort. We included 31,751 participants who were free of coronary heart disease (CHD), stroke, cancer, or severely abnormal electrocardiogram (ECG) at baseline.
Source: The American Journal of Cardiology - October 23, 2018 Category: Cardiology Authors: Shiqi He, Wenhui Lei, Jun Li, Kuai Yu, Yanqiu Yu, Lue Zhou, Xiaomin Zhang, Meian He, Huan Guo, Handong Yang, Tangchun Wu Source Type: research

Pages: 1  2